Potential Phytocompounds to Inhibit Human Polo-Like Kinase 1 in Cancer Therapy

被引:0
|
作者
Davis, Sangeetha P. [1 ]
Baby, Bincy [1 ]
Vipin, A. M. [1 ]
Kumar, Mala S. [1 ]
Nazeem, P. A. [1 ]
机构
[1] Kerala Agr Univ, Coll Hort, Bioinformat Ctr, IT BT Complex,Vellanikkara PO, Trichur 680656, Kerala, India
关键词
Discovery Studio 4.0; Human polo-like kinases; Molecular docking; Phytocompounds;
D O I
暂无
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cancer is a potential fatal disease characterized by the uncontrolled growth and spread of abnormal cells. Polo-like kinases (Plks) are serine/threonine protein kinases which play critical role in regulating cell cycle. Deregulated expression of Plks is detected in many types of cancer and is associated with oncogenesis. Though there are five Plk homologous, Plk 1 is identified as the best target to defend uncontrolled cell growth. Natural compounds from plant resource are being exploited recently on a large scale for treating various diseases. The aim of this study is to identify the inhibitory activity of selected phytochemicals on Plk 1 protein so as to develop effective drugs based on natural compounds. In silico docking analysis is a successful way of screening molecules so as to confirm their inhibitory activity against respective targets. About 574 phytocompounds of various conformations were docked with the target protein Plk 1 using the software Discovery Studio version 4.0. The most effective ones were identified based on interaction energy and docking score. Phytocompounds such as ferulic acid, caffeic acid and N-methyltyramine from the common medicinal plants like Curcuma longa, Pseudarthria viscida and Wrightia tinctoria showed strong anticancer activity through the suppression of Plk 1.
引用
收藏
页码:1257 / 1263
页数:7
相关论文
共 50 条
  • [21] Polo-Like Kinases in Colorectal Cancer: Potential for Targeted Therapy
    Kazazian, Karineh
    Brashavitskaya, Olga
    Zih, Francis S. W.
    Berger-Richardson, David
    Xu, Roland S. Z.
    Pacholczyk, Karina
    Macmillan, Jennifer
    Swallow, Carol J.
    CURRENT COLORECTAL CANCER REPORTS, 2015, 11 (04) : 187 - 199
  • [22] Polo-Like Kinase 1 in the Life and Death of Cancer Cells
    Liu, Xiaoqi
    Erikson, Raymond L.
    CELL CYCLE, 2003, 2 (05) : 424 - 425
  • [23] Modulating Polo-Like Kinase 1 as a Means for Cancer Chemoprevention
    Travis L. Schmit
    Mark C. Ledesma
    Nihal Ahmad
    Pharmaceutical Research, 2010, 27 : 989 - 998
  • [24] Molecular interactions of polo-like kinase 1 in human cancers
    Ng, Wayne Tiong Weng
    Shin, Joo-Shik
    Roberts, Tara Laurine
    Wang, Bin
    Lee, Cheok Soon
    JOURNAL OF CLINICAL PATHOLOGY, 2016, 69 (07) : 557 - 562
  • [25] Potential Tumor Suppressor Role of Polo-like Kinase 5 in Cancer
    Su, Shengqin
    Ndiaye, Mary Ann
    Guzman-Perez, Glorimar
    Baus, Rebecca Michael
    Huang, Wei
    Patankar, Manish Suresh
    Ahmad, Nihal
    CANCERS, 2023, 15 (22)
  • [26] Structure of the catalytic domain of human polo-like kinase 1
    Kothe, Michael
    Kohls, Darcy
    Low, Simon
    Coli, Rocco
    Cheng, Alan C.
    Jacques, Suzanne L.
    Johnson, Theresa L.
    Lewis, Cristina
    Loh, Christine
    Nonomiya, Jim
    Sheils, Alissa L.
    Verdries, Kimberly A.
    Wynn, Thomas A.
    Kuhn, Cyrille
    Ding, Yuan-Hua
    BIOCHEMISTRY, 2007, 46 (20) : 5960 - 5971
  • [27] Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
    B T Gjertsen
    P Schöffski
    Leukemia, 2015, 29 : 11 - 19
  • [28] Human Polo-like Kinase Inhibitors as Antiplasmodials
    Bohmer, Monica J.
    Wang, Jinhua
    Istvan, Eva S.
    Luth, Madeline R.
    Collins, Jennifer E.
    Huttlin, Edward L.
    Wang, Lushun
    Mittal, Nimisha
    Hao, Mingfeng
    Kwiatkowski, Nicholas P.
    Gygi, Steven P.
    Chakrabarti, Ratna
    Deng, Xianming
    Goldberg, Daniel E.
    Winzeler, Elizabeth A.
    Gray, Nathanael S.
    Chakrabarti, Debopam
    ACS INFECTIOUS DISEASES, 2023, 9 (04): : 1004 - 1021
  • [29] Modulating Polo-Like Kinase 1 as a Means for Cancer Chemoprevention
    Schmit, Travis L.
    Ledesma, Mark C.
    Ahmad, Nihal
    PHARMACEUTICAL RESEARCH, 2010, 27 (06) : 989 - 998
  • [30] Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
    Gjertsen, B. T.
    Schoffski, P.
    LEUKEMIA, 2015, 29 (01) : 11 - 19